Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Fecteau on Salvage Therapy for Recurrent Prostate Cancer

January 20th 2023

Ryan Fecteau, MD, PhD, discusses the navigation of salvage treatment options for patients experiencing isolated prostate cancer recurrence.

Dr. Morgans on the Current Treatment Landscape For mHSPC

January 18th 2023

Alicia Morgans, MD, MPH, discusses current androgen deprivation therapy combinations and the investigation of radiopharmaceutical combinations for metastatic hormone-sensitive prostate cancer.

MRI-Guided Radiotherapy Significantly Reduces Genitourinary, Gastrointestinal AEs in Prostate Cancer

January 17th 2023

Patients who received MRI-guided stereotactic body radiotherapy for prostate cancer experienced fewer moderate acute physician-scored genitourinary and gastrointestinal adverse effects compared with those who received computed tomography–guided stereotactic body radiotherapy.

Dr. Dorff on the Exploration of Triplet Combination Therapies in mHSPC

January 12th 2023

Tanya Dorff, MD, discusses the exploration of triplet combination therapies in patients with metastatic hormone-sensitive prostate cancer.

ADXS-504 Study Increases Enrollment After Confirming Safety in Recurrent Early Prostate Cancer

January 12th 2023

ADXS-504, an investigational off-the-shelf neoantigen therapy, has been reported to be well tolerated and safe in patients with biochemically recurrent early prostate cancer.

BXCL701 Plus Pembrolizumab Generates Promising Responses in Small Cell Neuroendocrine mCRPC

January 11th 2023

The combination of BXCL701 and pembrolizumab produced encouraging responses in patients with small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer, according to topline data from a phase 2 trial.

Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC

January 10th 2023

Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.

Metastatic CRPC Management: Future Directions in Care

January 9th 2023

Closing out their review of the metastatic CRPC treatment paradigm, Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, look toward future evolutions in care.

TAVT-45 Granules Show Equivalence to Abiraterone Tablets in Metastatic Prostate Cancer

January 5th 2023

Abiraterone acetate granules for oral suspension demonstrated therapeutic equivalence and comparable safety to the original formulation of abiraterone acetate in patients with metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

Addressing Barriers to Care in Metastatic Castration-Resistant Prostate Cancer

January 2nd 2023

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, share perspective on the challenges inherent in delivering novel therapy to patients diagnosed with metastatic CRPC.

Metastatic CRPC: Selecting Patients for Cabazitaxel or Radiotherapy

January 2nd 2023

Comprehensive insight on factors that may influence the selection of cabazitaxel or radiotherapy for patients with metastatic castration-resistant prostate cancer.

A “Crazy” Idea Leads to a Revolution in Prostate Cancer Care

December 28th 2022

An unshakeable belief in the power of the immune system and a deep-seated desire to make the world a better place have guided Eric J. Small, MD, throughout his career.

Optimizing Patient Selection for Cabazitaxel Therapy in Metastatic CRPC

December 26th 2022

A brief review of factors that may influence an academic or community physician’s choice to utilize cabazitaxel in the setting of metastatic castration-resistant prostate cancer.

Metastatic CRPC: Considering Use of Combination Cabazitaxel/Carboplatin

December 26th 2022

Switching their focus to combination therapy in metastatic CRPC, expert oncologists review trial results from a study analyzing cabazitaxel/carboplatin therapy.

European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC

December 21st 2022

The European Commission has approved the combination of olaparib plus abiraterone acetate and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.

Dr. Mian on the Investigation into the Synchronous Up-front Setting of Metastatic Prostate Cancer

December 19th 2022

Omar Mian, MD, PhD, discusses the ongoing investigation into the synchronous up-front setting of metastatic prostate cancer.

Interpreting Data From the CARD Trial in Metastatic CRPC

December 19th 2022

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, review data from the CARD trial and discuss the nuanced selection and sequencing of treatment in metastatic CRPC.

The PROSELICA Trial: Cabazitaxel Dosing in Metastatic CRPC

December 19th 2022

Expert perspectives on the PROSELICA trial, which helped inform optimal dosing strategies with cabazitaxel in metastatic castration-resistant prostate cancer.

An Economic Evaluation of Cabazitaxel Versus a Second Androgen Receptor‑targeted Agent (ARTA) for Patients with Metastatic Castration‑resistant Prostate Cancer Previously Treated with Docetaxel and an ARTA: the United States Payer Perspective

December 16th 2022

Dr Thomas Hutson reviews recently published data on patient outcomes and estimated healthcare costs associated with use of third-line cabazitaxel versus a second ARTA in patients with metastatic castration-resistant prostate cancer (CRPC).

FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC

December 15th 2022

The FDA has told AstraZeneca and MSD that the agency will extend the Prescription Drug User Fee Act date by 3 months to provide further time for a full review of the supplementary new drug application for olaparib plus abiraterone and prednisone or prednisolone for patients with mCRPC.